Undisclosed BLA-Stage Asset

About XOMA

XOMA Royalty Corporation has strategically transformed from a traditional drug discovery company into a specialized biotech royalty aggregator, acquiring future economic rights to milestone and royalty payments from partnered therapeutic assets. Its mission is to provide non-dilutive, non-recourse capital to biotech innovators, building a diversified portfolio of over 120 assets to mitigate binary risk while participating in the upside of drug development. Key achievements include securing a $140 million financing facility backed by its VABYSMO® royalties and building a portfolio with its first FDA-approved asset, VABYSMO, now generating revenue. The strategy focuses on leveraging scientific diligence to acquire rights to pre-commercial assets with blockbuster potential, operated by well-capitalized partners, under a capital-efficient corporate structure.

Therapeutic Areas

Other Undisclosed (Likely Oncology/Immunology) Drugs